These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27796680)

  • 1. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Fiala O; Hosek P; Pesek M; Finek J; Racek J; Stehlik P; Sorejs O; Minarik M; Benesova L; Celer A; Nemcova I; Kucera R; Topolcan O
    Anticancer Res; 2017 Nov; 37(11):6469-6476. PubMed ID: 29061834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
    Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
    Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K
    Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
    Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
    Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid onset of conjunctivitis associated with overdosing of erlotinib.
    Sun P; Long J; Chen P; He Q; Gao X; Li S
    J Clin Pharm Ther; 2018 Apr; 43(2):296-298. PubMed ID: 29069525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of erlotinib in a pregnant woman with advanced non-small cell lung cancer and observation of the effects on the child growth.
    Aida Y; Ohgami M; Mukai Y; Matsuyama M; Obata-Yasuoka M; Satoh T; Homma M; Sekine I; Hizawa N
    Br J Clin Pharmacol; 2024 Oct; 90(10):2554-2561. PubMed ID: 38889797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of erlotinib in daily practice: a study on adherence and patients' experiences.
    Timmers L; Boons CC; Mangnus D; Moes JE; Swart EL; Boven E; Smit EF; Hugtenburg JG
    BMC Cancer; 2011 Jul; 11():284. PubMed ID: 21722354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.